<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69094">
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
        <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
        <link_text>Link to the current ClinicalTrials.gov record.</link_text>
        <url>https://clinicaltrials.gov/show/NCT02206334</url>
    </required_header>
    <id_info>
        <org_study_id>NRG-BR001</org_study_id>
        <secondary_id>NCI-2014-00702</secondary_id>
        <secondary_id>NRG BR001</secondary_id>
        <secondary_id>NRG-BR001</secondary_id>
        <secondary_id>NRG-BR001</secondary_id>
        <secondary_id>U10CA180868</secondary_id>
        <secondary_id>U10CA021661</secondary_id>
        <nct_id>NCT02206334</nct_id>
    </id_info>
    <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer</brief_title>
    <official_title>A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases</official_title>
    <sponsors>
        <lead_sponsor>
            <agency>NRG Oncology</agency>
            <agency_class>Other</agency_class>
        </lead_sponsor>
        <collaborator>
            <agency>National Cancer Institute (NCI)</agency>
            <agency_class>NIH</agency_class>
        </collaborator>
    </sponsors>
    <source>NRG Oncology</source>
    <oversight_info>
        <has_dmc>Yes</has_dmc>
    </oversight_info>
    <brief_summary>
        <textblock>
            This phase I trial studies the side effects and the best dose of stereotactic body radiation
            therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate
            cancer that has spread to other parts of the body. Stereotactic body radiation therapy
            delivers fewer, tightly-focused, high doses of radiation therapy to all known sites of
            cancer in the body while minimizing radiation exposure of surrounding normal tissue.
        </textblock>
    </brief_summary>
    <detailed_description>
        <textblock>
            PRIMARY OBJECTIVES:

            I. To determine the recommended stereotactic body radiation therapy (SBRT) dose for each of
            the metastatic locations being treated given the individual and overlapping fields when
            multiple metastases are treated with SBRT in a national clinical trials network setting.

            SECONDARY OBJECTIVES:

            I. To estimate rates of &gt;= grade 3 Common Terminology Criteria for Adverse Events (CTCAE),
            version (v.) 4.0 adverse events other than a dose-limiting toxicity (DLT) which is possibly,
            probably, or definitely related to treatment and which occurs within 6 months from the start
            of SBRT to multiple metastases.

            II. To estimate the rates of long-term adverse events occurring up to 2 years from the end
            of SBRT.

            III. To explore the most appropriate and clinically relevant technological parameters to
            ensure quality and effectiveness throughout radiation therapy processes, including imaging,
            simulation, patient immobilization, target and critical structure definition, treatment
            planning, image guidance and delivery.

            OUTLINE:

            Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all
            existing metastases over 1-3 weeks with at least 40 hours between treatments for an
            individual metastasis.

            After completion of study treatment, patients are followed up at 35-45 days and then every 3
            months for 2 years.
        </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date>August 2014</start_date>
    <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
        <intervention_model>Single Group Assignment</intervention_model>
        <primary_purpose>Treatment</primary_purpose>
        <masking>Open Label</masking>
    </study_design_info>
    <primary_outcome>
        <measure>Dose-limiting toxicity (DLT) scored according to the National Cancer Institute (NCI) CTCAE version 4.0 for each of 7 metastatic locations when multiple metastases are treated with SBRT</measure>
        <time_frame>Within 6 months from the start of treatment; for each of the 7 metastatic locations, analysis occurs after 6 evaluable patients have been followed for a minimum of 6 months from the start of treatment</time_frame>
        <description>Adverse events outlined by metastatic location (full detail in protocol) reported as being probably or definitely related to protocol treatment.</description>
    </primary_outcome>
    <secondary_outcome>
        <measure>Rate of long-term adverse events, scored according to the NCI CTCAE v. 4.0</measure>
        <time_frame>Up to 2 years from end of treatment; analysis occurs after all patients have been potentially followed for 2 years from registration</time_frame>
        <description>Adverse events reported as being possibly, probably, or definitely related to protocol treatment.</description>
    </secondary_outcome>
    <secondary_outcome>
        <measure>Rates of &gt;= grade 3 adverse events, scored according to NCI CTCAE v. 4.0</measure>
        <time_frame>Within 6 months from the start of treatment; analysis occurs after all patients have been followed for a minimum of 6 months from the start of treatment</time_frame>
        <description>Adverse events (other than DLTs) reported as being possibly, probably, or definitely related to protocol treatment.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">84</enrollment>
    <condition>Male Breast Carcinoma</condition>
    <condition>Prostate Adenocarcinoma</condition>
    <condition>Recurrent Breast Carcinoma</condition>
    <condition>Recurrent Non-Small Cell Lung Carcinoma</condition>
    <condition>Recurrent Prostate Carcinoma</condition>
    <condition>Stage IV Breast Cancer</condition>
    <condition>Stage IV Non-Small Cell Lung Cancer</condition>
    <condition>Stage IV Prostate Cancer</condition>
    <arm_group>
        <arm_group_label>Treatment (stereotactic body radiation therapy)</arm_group_label>
        <arm_group_type>Experimental</arm_group_type>
        <description>Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.</description>
    </arm_group>
    <intervention>
        <intervention_type>Radiation</intervention_type>
        <intervention_name>Stereotactic Radiosurgery</intervention_name>
        <description>Undergo SBRT</description>
        <arm_group_label>Treatment (stereotactic body radiation therapy)</arm_group_label>
        <other_name>Stereotactic External Beam Irradiation</other_name>
        <other_name>stereotactic external-beam radiation therapy</other_name>
        <other_name>Stereotactic Radiation Therapy</other_name>
        <other_name>Stereotactic Radiotherapy</other_name>
        <other_name>stereotaxic radiation therapy</other_name>
        <other_name>stereotaxic radiosurgery</other_name>
    </intervention>
    <eligibility>
        <criteria>
            <textblock>
                Inclusion Criteria:

                -  Metastatic breast cancer (MBC) OR metastatic non-small cell lung cancer (NSCLC) OR
                metastatic adenocarcinoma of the prostate; the sites of allowed metastases are:
                peripheral lung, central lung, mediastinal/cervical lymph node, liver,
                spinal/paraspinal, osseous, and abdominal-pelvic

                -  NOTE: after the required number of evaluable patients have been accrued for a
                given dose level, the accrual for that metastatic location will be temporarily
                suspended while the safety of that dose level is assessed; a patient can only be
                entered onto the trial if all of their metastatic locations are open to accrual
                (e.g. if central lung is temporarily suspended for safety assessment and the
                patient has a central lung metastases, regardless of other metastases, they
                cannot enroll until the safety of dose to central lung is determined)

                -  Primary tumor site without progression at registration

                -  All metastases not resected must be amenable to SBRT

                -  The patient must meet ONE of the three following criteria:

                -  3-4 radiographically distinct metastases of any distribution in the allowed
                anatomical sites OR

                -  2 radiographically distinct metastases that must be anatomically close (i.e.,
                with less than or equal to 5 cm of normal tissue between them) OR

                -  3 or 4 distinct metastasis, 2 or 3 to be treated with SBRT and the other (s)
                having been surgically removed

                -  Evaluation by a radiation oncologist within 45 days prior to study registration

                -  Evaluation by a medical oncologist within 45 days prior to study registration

                -  The following imaging workup to document metastases within 45 days prior to study
                registration:

                -  Computed tomography (CT) scans of the chest, abdomen and pelvis with
                radionuclide bone scan OR whole body positron emission tomography (PET)/CT

                -  History/physical examination within 45 days prior to study registration

                -  Zubrod performance status =&lt; 2 within 45 days prior to study registration

                -  Age &gt;= 18 years

                -  Absolute neutrophil count (ANC) &gt;= 500 cells/mm^3

                -  Platelets &gt;= 50,000 /mm^3

                -  Hemoglobin &gt;= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
                hemoglobin [Hgb] &gt;= 8.0 g/dl is acceptable)

                -  If liver metastases present, aspartate aminotransferase (AST) and alanine
                aminotransferase (ALT) must be &lt; 3 x upper limit of normal (ULN)

                -  Patient must provide study specific informed consent prior to study entry

                -  For females of child-bearing potential, negative serum/urine pregnancy test within 14
                days prior to study registration

                Exclusion Criteria:

                -  Progression of primary tumor site (breast, prostate, or lung) at time of registration

                -  Metastases with indistinct borders making targeting not feasible

                -  Known brain metastases

                -  Prior palliative radiotherapy to metastases

                -  Metastases located within 3 cm of the previously irradiated structures:

                -  Spinal cord previously irradiated to &gt; 40 Gy (delivered in =&lt; 3 Gy/fraction)

                -  Brachial plexus previously irradiated to &gt; 50 Gy (delivered in =&lt; 3 Gy/fraction)

                -  Small intestine, large intestine, or stomach previously irradiated to &gt; 45 Gy
                (delivered in =&lt; 3 Gy/fraction)

                -  Brain stem previously irradiated to &gt; 50 Gy (delivered in =&lt; 3 Gy/fraction)

                -  Whole lung previously irradiated with prior volume 20 Gy (V20Gy) &gt; 30%
                (delivered in =&lt; 3 Gy/fraction)

                -  Primary tumor irradiated with SBRT

                -  Metastasis irradiated with SBRT

                -  Severe, active co-morbidity, defined as follows:

                -  Unstable angina and/or congestive heart failure requiring hospitalization within
                the last 6 months prior to registration

                -  Transmural myocardial infarction within the last 6 months prior to registration

                -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                time of registration

                -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                requiring hospitalization or precluding study therapy within 30 days prior to
                registration

                -  Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C
                hepatic disease

                -  Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)
                4 count &lt; 200 cells/microliter; note that patients who are HIV positive are
                eligible, provided they are under treatment with highly active antiretroviral
                therapy (HAART) and have a CD4 count &gt;= 200 cells/microliter within 30 days
                prior to registration; note also that HIV testing is not required for
                eligibility for this protocol

                -  End-stage renal disease (i.e., on dialysis or dialysis has been recommended)

                -  Pregnancy or women of childbearing potential not willing/able to use medically
                acceptable forms of contraception during protocol treatment or for at least 6 months
                following treatment
            </textblock>
        </criteria>
        <gender>All</gender>
        <minimum_age>18 Years</minimum_age>
        <maximum_age>N/A</maximum_age>
        <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
        <last_name>Steven Chmura</last_name>
        <role>Principal Investigator</role>
        <affiliation>NRG Oncology</affiliation>
    </overall_official>
    <location>
        <facility>
            <name>University of Alabama at Birmingham Cancer Center</name>
            <address>
                <city>Birmingham</city>
                <state>Alabama</state>
                <zip>35233</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Jennifer F. De Los Santos</last_name>
            <phone>205-978-3928</phone>
            <email>jdelossantos@uabmc.edu</email>
        </contact>
        <investigator>
            <last_name>Jennifer F. De Los Santos</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>The University of Arizona Medical Center-University Campus</name>
            <address>
                <city>Tucson</city>
                <state>Arizona</state>
                <zip>85724</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Baldassarre (. Stea</last_name>
            <phone>520-626-9008</phone>
        </contact>
        <investigator>
            <last_name>Baldassarre (. Stea</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>City of Hope Comprehensive Cancer Center</name>
            <address>
                <city>Duarte</city>
                <state>California</state>
                <zip>91010</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Savita V. Dandapani</last_name>
            <phone>800-826-4673</phone>
            <email>becomingapatient@coh.org</email>
        </contact>
        <investigator>
            <last_name>Savita V. Dandapani</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>UC San Diego Moores Cancer Center</name>
            <address>
                <city>La Jolla</city>
                <state>California</state>
                <zip>92093</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>James J. Urbanic</last_name>
            <phone>858-822-5354</phone>
            <email>cancercto@ucsd.edu</email>
        </contact>
        <investigator>
            <last_name>James J. Urbanic</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>USC / Norris Comprehensive Cancer Center</name>
            <address>
                <city>Los Angeles</city>
                <state>California</state>
                <zip>90033</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Eugene I. Chung</last_name>
            <phone>323-865-0451</phone>
            <email>eugene.chung@med.usc.edu</email>
        </contact>
        <investigator>
            <last_name>Eugene I. Chung</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Sutter General Hospital</name>
            <address>
                <city>Sacramento</city>
                <state>California</state>
                <zip>95816</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Christopher U. Jones</last_name>
            <phone>415-209-2686</phone>
            <email>bernicl@sutterhealth.org</email>
        </contact>
        <investigator>
            <last_name>Christopher U. Jones</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of California Davis Comprehensive Cancer Center</name>
            <address>
                <city>Sacramento</city>
                <state>California</state>
                <zip>95817</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Megan E. Daly</last_name>
            <phone>916-734-3089</phone>
        </contact>
        <investigator>
            <last_name>Megan E. Daly</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
            <address>
                <city>Aurora</city>
                <state>Colorado</state>
                <zip>80045</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Rachel A. Rabinovitch</last_name>
            <phone>720-848-0650</phone>
        </contact>
        <investigator>
            <last_name>Rachel A. Rabinovitch</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Florida</name>
            <address>
                <city>Gainesville</city>
                <state>Florida</state>
                <zip>32610</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Active, not recruiting</status>
    </location>
    <location>
        <facility>
            <name>University of Florida Health Science Center</name>
            <address>
                <city>Jacksonville</city>
                <state>Florida</state>
                <zip>32209</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Suspended</status>
    </location>
    <location>
        <facility>
            <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
            <address>
                <city>Miami</city>
                <state>Florida</state>
                <zip>33136</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Youssef Zeidan</last_name>
            <phone>305-243-5363</phone>
            <email>Sylvester@emergingmed.com</email>
        </contact>
        <investigator>
            <last_name>Youssef Zeidan</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Grady Health System</name>
            <address>
                <city>Atlanta</city>
                <state>Georgia</state>
                <zip>30303</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Pretesh R. Patel</last_name>
            <phone>404-778-1868</phone>
        </contact>
        <investigator>
            <last_name>Pretesh R. Patel</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Emory University Hospital Midtown</name>
            <address>
                <city>Atlanta</city>
                <state>Georgia</state>
                <zip>30308</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Pretesh R. Patel</last_name>
            <phone>404-778-1868</phone>
        </contact>
        <investigator>
            <last_name>Pretesh R. Patel</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Emory University/Winship Cancer Institute</name>
            <address>
                <city>Atlanta</city>
                <state>Georgia</state>
                <zip>30322</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Pretesh R. Patel</last_name>
            <phone>404-778-1868</phone>
        </contact>
        <investigator>
            <last_name>Pretesh R. Patel</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Northwest Community Hospital</name>
            <address>
                <city>Arlington Heights</city>
                <state>Illinois</state>
                <zip>60005</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Stephen S. Nigh</last_name>
            <phone>847-618-4968</phone>
        </contact>
        <investigator>
            <last_name>Stephen S. Nigh</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Northwestern University</name>
            <address>
                <city>Chicago</city>
                <state>Illinois</state>
                <zip>60611</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>John P. Hayes</last_name>
            <phone>312-695-1301</phone>
            <email>cancer@northwestern.edu</email>
        </contact>
        <investigator>
            <last_name>John P. Hayes</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Chicago Comprehensive Cancer Center</name>
            <address>
                <city>Chicago</city>
                <state>Illinois</state>
                <zip>60637</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Steven J. Chmura</last_name>
            <phone>773-834-7424</phone>
        </contact>
        <investigator>
            <last_name>Steven J. Chmura</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Decatur Memorial Hospital</name>
            <address>
                <city>Decatur</city>
                <state>Illinois</state>
                <zip>62526</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>James L. Wade</last_name>
            <phone>217-876-4740</phone>
            <email>kcheek@dmhhs.org</email>
        </contact>
        <investigator>
            <last_name>James L. Wade</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Loyola University Medical Center</name>
            <address>
                <city>Maywood</city>
                <state>Illinois</state>
                <zip>60153</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Abhishek A. Solanki</last_name>
            <phone>708-216-4498</phone>
            <email>abhishek.solanki@lumc.edu</email>
        </contact>
        <investigator>
            <last_name>Abhishek A. Solanki</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>OSF Saint Francis Medical Center</name>
            <address>
                <city>Peoria</city>
                <state>Illinois</state>
                <zip>61637</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>James L. Wade</last_name>
            <phone>217-876-4740</phone>
            <email>kcheek@dmhhs.org</email>
        </contact>
        <investigator>
            <last_name>James L. Wade</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Saint Vincent Anderson Regional Hospital/Cancer Center</name>
            <address>
                <city>Anderson</city>
                <state>Indiana</state>
                <zip>46016</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Alexander M. Yeh</last_name>
            <phone>765-646-8358</phone>
        </contact>
        <investigator>
            <last_name>Alexander M. Yeh</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Parkview Hospital Randallia</name>
            <address>
                <city>Fort Wayne</city>
                <state>Indiana</state>
                <zip>46805</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Brian K. Chang</last_name>
            <phone>260-373-8888</phone>
            <email>parkviewresearch@parkview.com</email>
        </contact>
        <investigator>
            <last_name>Brian K. Chang</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>IU Health Methodist Hospital</name>
            <address>
                <city>Indianapolis</city>
                <state>Indiana</state>
                <zip>46202</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>John A. Cox</last_name>
            <phone>317-944-0611</phone>
            <email>jcox23@iuhealth.org</email>
        </contact>
        <investigator>
            <last_name>John A. Cox</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Iowa Methodist Medical Center</name>
            <address>
                <city>Des Moines</city>
                <state>Iowa</state>
                <zip>50309</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Robert J. Behrens</last_name>
            <phone>515-282-2921</phone>
            <email>rbehrens@cancercenterofiowa.com</email>
        </contact>
        <investigator>
            <last_name>Robert J. Behrens</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Via Christi Regional Medical Center</name>
            <address>
                <city>Wichita</city>
                <state>Kansas</state>
                <zip>67214</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Shaker R. Dakhil</last_name>
            <phone>316-262-0706</phone>
            <email>shaker.dakhil@cancercenterofkansas.com</email>
        </contact>
        <investigator>
            <last_name>Shaker R. Dakhil</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Kentucky/Markey Cancer Center</name>
            <address>
                <city>Lexington</city>
                <state>Kentucky</state>
                <zip>40536</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Ronald C. McGarry</last_name>
            <phone>859-257-3379</phone>
        </contact>
        <investigator>
            <last_name>Ronald C. McGarry</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>The James Graham Brown Cancer Center at University of Louisville</name>
            <address>
                <city>Louisville</city>
                <state>Kentucky</state>
                <zip>40202</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Neal E. Dunlap</last_name>
            <phone>866-530-5516</phone>
        </contact>
        <investigator>
            <last_name>Neal E. Dunlap</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Maryland/Greenebaum Cancer Center</name>
            <address>
                <city>Baltimore</city>
                <state>Maryland</state>
                <zip>21201</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Steven J. Feigenberg</last_name>
            <phone>800-888-8823</phone>
        </contact>
        <investigator>
            <last_name>Steven J. Feigenberg</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Upper Chesapeake Medical Center</name>
            <address>
                <city>Bel Air</city>
                <state>Maryland</state>
                <zip>21014</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Navesh K. Sharma</last_name>
            <phone>800-888-8823</phone>
        </contact>
        <investigator>
            <last_name>Navesh K. Sharma</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Boston Medical Center</name>
            <address>
                <city>Boston</city>
                <state>Massachusetts</state>
                <zip>02118</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Lisa A. Kachnic</last_name>
            <phone>800-811-8480</phone>
            <email>lisa.a.kachnic@vanderbilt.edu</email>
        </contact>
        <investigator>
            <last_name>Lisa A. Kachnic</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Michigan Comprehensive Cancer Center</name>
            <address>
                <city>Ann Arbor</city>
                <state>Michigan</state>
                <zip>48109</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Daniel E. Spratt</last_name>
            <phone>734-763-7370</phone>
            <email>sprattda@med.umich.edu</email>
        </contact>
        <investigator>
            <last_name>Daniel E. Spratt</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Henry Ford Hospital</name>
            <address>
                <city>Detroit</city>
                <state>Michigan</state>
                <zip>48202</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Eleanor M. Walker</last_name>
            <phone>313-916-1784</phone>
        </contact>
        <investigator>
            <last_name>Eleanor M. Walker</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>McLaren Cancer Institute-Flint</name>
            <address>
                <city>Flint</city>
                <state>Michigan</state>
                <zip>48532</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Kiran Devisetty</last_name>
            <phone>989-667-6257</phone>
        </contact>
        <investigator>
            <last_name>Kiran Devisetty</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>21st Century Oncology-Troy</name>
            <address>
                <city>Troy</city>
                <state>Michigan</state>
                <zip>48098</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Frank A. Vicini</last_name>
            <phone>888-326-9729</phone>
        </contact>
        <investigator>
            <last_name>Frank A. Vicini</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Henry Ford Medical Center - West Bloomfield</name>
            <address>
                <city>West Bloomfield</city>
                <state>Michigan</state>
                <zip>48322</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Suspended</status>
    </location>
    <location>
        <facility>
            <name>Mercy Hospital</name>
            <address>
                <city>Coon Rapids</city>
                <state>Minnesota</state>
                <zip>55433</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Paul W. Sperduto</last_name>
            <phone>952-993-1517</phone>
            <email>MMCCOP@parknicollet.com</email>
        </contact>
        <investigator>
            <last_name>Paul W. Sperduto</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Mayo Clinic</name>
            <address>
                <city>Rochester</city>
                <state>Minnesota</state>
                <zip>55905</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Sean S. Park</last_name>
            <phone>507-538-7623</phone>
        </contact>
        <investigator>
            <last_name>Sean S. Park</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Washington University School of Medicine</name>
            <address>
                <city>Saint Louis</city>
                <state>Missouri</state>
                <zip>63110</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Clifford G. Robinson</last_name>
            <phone>800-600-3606</phone>
            <email>info@siteman.wustl.edu</email>
        </contact>
        <investigator>
            <last_name>Clifford G. Robinson</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Virtua Memorial</name>
            <address>
                <city>Mount Holly</city>
                <state>New Jersey</state>
                <zip>08060</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Suspended</status>
    </location>
    <location>
        <facility>
            <name>Cooper CyberKnife Center</name>
            <address>
                <city>Mount Laurel</city>
                <state>New Jersey</state>
                <zip>08054</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Suspended</status>
    </location>
    <location>
        <facility>
            <name>Virtua Voorhees</name>
            <address>
                <city>Voorhees</city>
                <state>New Jersey</state>
                <zip>08043</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Lemuel S. Ariaratnam</last_name>
            <phone>609-914-6762</phone>
        </contact>
        <investigator>
            <last_name>Lemuel S. Ariaratnam</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of New Mexico Cancer Center</name>
            <address>
                <city>Albuquerque</city>
                <state>New Mexico</state>
                <zip>87102</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Gregory Gan</last_name>
            <phone>505-272-6972</phone>
            <email>ggan@salud.unm.edu</email>
        </contact>
        <investigator>
            <last_name>Gregory Gan</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Montefiore Medical Center - Moses Campus</name>
            <address>
                <city>Bronx</city>
                <state>New York</state>
                <zip>10467-2490</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Nitin Ohri</last_name>
            <phone>718-904-2730</phone>
            <email>aecc@aecom.yu.edu</email>
        </contact>
        <investigator>
            <last_name>Nitin Ohri</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>University of Rochester</name>
            <address>
                <city>Rochester</city>
                <state>New York</state>
                <zip>14642</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Yuhchyau Chen</last_name>
            <phone>585-275-5830</phone>
        </contact>
        <investigator>
            <last_name>Yuhchyau Chen</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Duke University Medical Center</name>
            <address>
                <city>Durham</city>
                <state>North Carolina</state>
                <zip>27710</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Joseph K. Salama</last_name>
            <phone>888-275-3853</phone>
        </contact>
        <investigator>
            <last_name>Joseph K. Salama</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Cleveland Clinic Foundation</name>
            <address>
                <city>Cleveland</city>
                <state>Ohio</state>
                <zip>44195</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Samuel T. Chao</last_name>
            <phone>866-223-8100</phone>
        </contact>
        <investigator>
            <last_name>Samuel T. Chao</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Ohio State University Comprehensive Cancer Center</name>
            <address>
                <city>Columbus</city>
                <state>Ohio</state>
                <zip>43210</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Jose G. Bazan</last_name>
            <phone>800-293-5066</phone>
            <email>Jamesline@osumc.edu</email>
        </contact>
        <investigator>
            <last_name>Jose G. Bazan</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Delaware County Memorial Hospital</name>
            <address>
                <city>Drexel Hill</city>
                <state>Pennsylvania</state>
                <zip>19026</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Active, not recruiting</status>
    </location>
    <location>
        <facility>
            <name>Reading Hospital</name>
            <address>
                <city>West Reading</city>
                <state>Pennsylvania</state>
                <zip>19611</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Terrence P. Cescon</last_name>
            <phone>610-988-9323</phone>
        </contact>
        <investigator>
            <last_name>Terrence P. Cescon</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Medical University of South Carolina</name>
            <address>
                <city>Charleston</city>
                <state>South Carolina</state>
                <zip>29425</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>David T. Marshall</last_name>
            <phone>843-792-9321</phone>
        </contact>
        <investigator>
            <last_name>David T. Marshall</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Self Regional Healthcare</name>
            <address>
                <city>Greenwood</city>
                <state>South Carolina</state>
                <zip>29646</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>David T. Marshall</last_name>
            <phone>843-792-9321</phone>
        </contact>
        <investigator>
            <last_name>David T. Marshall</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Huntsman Cancer Institute/University of Utah</name>
            <address>
                <city>Salt Lake City</city>
                <state>Utah</state>
                <zip>84112</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Withdrawn</status>
    </location>
    <location>
        <facility>
            <name>Gundersen Lutheran Medical Center</name>
            <address>
                <city>La Crosse</city>
                <state>Wisconsin</state>
                <zip>54601</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Collin D. Driscoll</last_name>
            <phone>608-775-4411</phone>
            <email>cancerctr@gundersenhealth.org</email>
        </contact>
        <investigator>
            <last_name>Collin D. Driscoll</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Froedtert and the Medical College of Wisconsin</name>
            <address>
                <city>Milwaukee</city>
                <state>Wisconsin</state>
                <zip>53226</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Elizabeth M. Gore</last_name>
            <phone>414-805-4380</phone>
        </contact>
        <investigator>
            <last_name>Elizabeth M. Gore</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Zablocki Veterans Administration Medical Center</name>
            <address>
                <city>Milwaukee</city>
                <state>Wisconsin</state>
                <zip>53295</zip>
                <country>United States</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Elizabeth M. Gore</last_name>
            <phone>414-805-4369</phone>
            <email>egore@mcw.edu</email>
        </contact>
        <investigator>
            <last_name>Elizabeth M. Gore</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>CHUM - Hopital Notre-Dame</name>
            <address>
                <city>Montreal</city>
                <state>Quebec</state>
                <zip>H2L 4M1</zip>
                <country>Canada</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Philip Wong</last_name>
            <phone>514-890-8000</phone>
            <phone_ext>23611</phone_ext>
            <email>sylvie.beaudoin.chum@ssss.gouv.qc.ca</email>
        </contact>
        <investigator>
            <last_name>Philip Wong</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Jewish General Hospital</name>
            <address>
                <city>Montreal</city>
                <state>Quebec</state>
                <zip>H3T 1E2</zip>
                <country>Canada</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Thierry M. Muanza</last_name>
            <phone>514-934-4400</phone>
            <email>tmuanza@jgh.mcgill.ca</email>
        </contact>
        <investigator>
            <last_name>Thierry M. Muanza</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location>
        <facility>
            <name>Cantonal Hospital of Aarau</name>
            <address>
                <city>Aarau</city>
                <zip>5001</zip>
                <country>Switzerland</country>
            </address>
        </facility>
        <status>Recruiting</status>
        <contact>
            <last_name>Stephan B. Bodis</last_name>
            <phone>41-62-838-5370</phone>
            <email>stephan.bodis@ksa.ch</email>
        </contact>
        <investigator>
            <last_name>Stephan B. Bodis</last_name>
            <role>Principal Investigator</role>
        </investigator>
    </location>
    <location_countries>
        <country>Canada</country>
        <country>Switzerland</country>
        <country>United States</country>
    </location_countries>
    <verification_date>June 2016</verification_date>
    <lastchanged_date>June 17, 2016</lastchanged_date>
    <firstreceived_date>July 30, 2014</firstreceived_date>
    <responsible_party>
        <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
        <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
        <mesh_term>Breast Neoplasms</mesh_term>
        <mesh_term>Carcinoma</mesh_term>
        <mesh_term>Lung Neoplasms</mesh_term>
        <mesh_term>Prostatic Neoplasms</mesh_term>
        <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
        <mesh_term>Adenocarcinoma</mesh_term>
        <mesh_term>Breast Neoplasms, Male</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                -->
</clinical_study>